Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Disease × alovudine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 8 Breast Neoplasms 5 Neoplasms 4 Head and Neck Neoplasms 3 Central Nervous System Neoplasms 3 Uterine Cervical Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 2 Prostatic Neoplasms 2 Oligodendroglioma 2 Glioma 2 Glioblastoma 2 Ependymoma 2 Astrocytoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Melanoma 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Hypoxia 1 Histologically-confirmed Malignancies 1 Gliosarcoma 1 Endometrial Neoplasms 1 Disease 1

Interventions

Blood Specimen Collection 8 Surveys and Questionnaires 5 Magnetic Resonance Spectroscopy 5 Biopsy 5 Colonoscopy 4 Biopsy, Fine-Needle 4 Tomography, X-Ray Computed 3 Surgical Procedures, Operative 3 Prednisone 3 Mammography 3 Magnetic Resonance Imaging 3 Liquid Biopsy 3 Lenalidomide 3 Interviews as Topic 3 Diagnostic Tests, Routine 3 weifuchun 2 Urination 2 Preoperative Exercise 2 Positron Emission Tomography Computed Tomography 2 Methods 2 Melphalan 2 Immunohistochemistry 2 Gemcitabine 2 Dexamethasone 2 Dermoscopy 2 Cyclophosphamide 2 Clinical Laboratory Techniques 2 vistusertib 1 venetoclax 1 tivozanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00633958 2021-10-20

FLT

Dana-Farber Cancer Institute

Phase 1 Terminated

Disease, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡